Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2019-09-28
2019-10-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cascade Continuous Glucose Monitor (CGM) 15-Day US Performance Assessment
NCT04397965
Glucomen Day Cascade CGM System 21-Day Wear Study
NCT05460260
Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System
NCT01514305
Performance Evaluation by the User of BGM Contour Care According to ISO 15197:2015
NCT06937736
Assessment of Blood Glucose Monitoring Systems
NCT01909687
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Continuous Monitoring
Single Arm, Randomized
Cascade Continuous Glucose Monitoring System
Continuous Glucose Monitoring for 15 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cascade Continuous Glucose Monitoring System
Continuous Glucose Monitoring for 15 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of type 1 or type 2 (on insulin therapy) diabetes mellitus for at least 6 months
* 18 years of age or older
* Currently self-monitoring capillary blood glucose (on average at least three times per day or more) or on a CGM for at least three months
* Willing to have blood glucose levels manipulated into high and low glucose levels during in clinic days if deemed appropriate per the protocol based on insulin use.
* Willing to follow all study procedures, including attending all clinic visits during which a venous line will be inserted for blood sampling, wearing CGM sensors for entire study, performing fingertip glucose tests for self-monitoring and calibration, and keeping a diary of activities.
* Be willing to wear two investigational CGM devices.
Exclusion Criteria
* Magnetic Resonance Imaging (MRI) scheduled during CGM sensor wear period
* Persons with type 2 diabetes using diet and exercise only for diabetes management
* Used an investigational drug within 30 days prior to study entry
* Hematocrit \< 32% (obtained during screening)
* Inadequate veins (in the opinion of the investigator) or known contraindication to placement of a dedicated peripheral line for venous blood withdrawal
* Symptomatic coronary artery disease with a history of angina, or history of a myocardial infarction or coronary intervention (e.g., percutaneous transluminal coronary angioplasty \[PTCA\], stent placement), or coronary artery bypass graft (CABG) within the past six months
* Diagnosis of the following diabetic autonomic neuropathies: orthostatic hypotension, heart rate anomalies, gastroparesis
* Cerebrovascular incident within the past six month
* History or presence of eczema, psoriasis, atopic or contact dermatitis
* Subject is pregnant at the start of the study.
* Current use or within one-week exposure to topical medications at the proposed insertion sites
* Seizure disorder (epilepsy)
* Malignancy within the past five years, except basal cell or squamous cell skin cancers
* Major surgical operation within 30 days prior to screening
* Other medical conditions that would pose safety concerns, interfere with study conduct or seriously compromise study integrity (reason for exclusion will be clearly documented by investigator or designee)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
WaveForm Technologies Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maja Navodnik Peložnik, MD
Role: PRINCIPAL_INVESTIGATOR
Splošna bolnišnica Celje
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Splošna bolnišnica Celje
Celje, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PR-19-0032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.